MedPath

CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST

CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST logo
🇬🇧United Kingdom
Ownership
Subsidiary
Established
1992-11-04
Employees
10K
Market Cap
-
Website
http://www.cuh.org.uk

Clinical Trials

340

Active:89
Completed:151

Trial Phases

6 Phases

Early Phase 1:1
Phase 1:48
Phase 2:46
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (259 trials with phase data)• Click on a phase to view related trials

Not Applicable
128 (49.4%)
Phase 1
48 (18.5%)
Phase 2
46 (17.8%)
Phase 3
25 (9.7%)
Phase 4
11 (4.2%)
Early Phase 1
1 (0.4%)

PARTial BREast RECONstruction With Chest Wall Perforator Flap

Recruiting
Conditions
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Breast Carcinoma
Breast Neoplasms
Breast Surgery
Breast Reconstruction Surgery
First Posted Date
2024-12-11
Last Posted Date
2024-12-11
Lead Sponsor
Cambridge University Hospitals NHS Foundation Trust
Target Recruit Count
1001
Registration Number
NCT06728527
Locations
🇬🇧

Cambridge University Hospitals NHS Trust, Cambridge, Cambridgeshire, United Kingdom

Utilising AI Analysis of Sounds To prEdict heaRt failurE decOmpensation

Not yet recruiting
Conditions
Heart Failure
First Posted Date
2024-08-15
Last Posted Date
2024-08-15
Lead Sponsor
Cambridge University Hospitals NHS Foundation Trust
Target Recruit Count
250
Registration Number
NCT06555757

PDE3B in Metabolic Regulation

Not yet recruiting
Conditions
Cardiometabolic Syndrome
Cardiovascular Diseases
Type 2 Diabetes
First Posted Date
2024-08-01
Last Posted Date
2024-08-01
Lead Sponsor
Cambridge University Hospitals NHS Foundation Trust
Target Recruit Count
40
Registration Number
NCT06533007

Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study

Recruiting
Conditions
Acute Coronary Syndromes
Interventions
Drug: Dextrose 5% in water
First Posted Date
2024-05-24
Last Posted Date
2024-06-10
Lead Sponsor
Cambridge University Hospitals NHS Foundation Trust
Target Recruit Count
60
Registration Number
NCT06427694
Locations
🇬🇧

Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom

Validation of AI Models to Measure Physical Activity After a Stroke

Recruiting
Conditions
Stroke
First Posted Date
2023-09-11
Last Posted Date
2023-09-11
Lead Sponsor
Cambridge University Hospitals NHS Foundation Trust
Target Recruit Count
34
Registration Number
NCT06030323
Locations
🇬🇧

Cambridge University Hospital NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 31
  • Next

News

NIHR Pilots 'Just in Time' Clinical Trial Initiative for Pancreatic Cancer Using Pembrolizumab-Olaparib Combination

The National Institute for Health and Care Research is piloting a 'Just in Time' scheme that could reduce clinical trial setup time from months to days, potentially improving patient access to trials closer to home.

Capsule Sponge Test Shows Promise as Alternative to Endoscopy for Barrett's Esophagus Monitoring

A new "pill-on-a-string" capsule sponge test successfully identified 54% of Barrett's esophagus patients as low-risk, potentially eliminating the need for invasive endoscopy surveillance in these cases.

First European Patient Receives Breakthrough Treatment for Ultra-Rare APDS Immune Disorder

Mary Catchpole, 19, becomes the first European patient to receive leniolisib (Joenja), a newly approved targeted treatment for activated PI3-kinase delta syndrome (APDS), a rare inherited immune disorder.

NHS Becomes First European Health System to Trial Revolutionary Histotripsy Cancer Treatment

The NHS will be the first health system in Europe to trial histotripsy, a non-invasive ultrasound technology that destroys liver tumors using sound waves to create "bubble clouds" that pulverize cancer cells.

Olaparib Before Surgery Shows 100% Survival Rate in BRCA-Mutated Breast Cancer Patients

A groundbreaking clinical trial led by Addenbrooke's Hospital demonstrates 100% three-year survival rate for patients with BRCA-mutated breast cancer when treated with olaparib plus chemotherapy before surgery.

Archer Platform Launches at Cambridge University Hospitals to Revolutionize Clinical Trial Data Management

IgniteData, AstraZeneca, and Cambridge University Hospitals have launched the Archer platform in a Phase 3 clinical trial, automating data transfer between electronic health records and clinical trial databases.

Morning Asthma Testing Yields More Reliable Results, Study Reveals Significant Seasonal Variations

Research analyzing 1,600 patient records shows asthma spirometry tests are 8% more reliable for each hour closer to 8:30 AM, highlighting the impact of circadian rhythms on diagnostic accuracy.

UK-First Study on Pediatric Brain Trauma Features Remarkable Recovery of 12-Year-Old Quad Bike Accident Survivor

A groundbreaking UK study involving 135 children across ten pediatric intensive care units examines pressure reactivity index monitoring in traumatic brain injuries, aiming to improve treatment outcomes.

Key Advances in Inflammatory Bowel Disease: New Therapies, Treatment Strategies, and Long-Term Data

Early, intensive 'top-down' therapy with TNF blockers plus immunomodulators shows superior outcomes compared to the traditional 'step-up' approach for newly diagnosed Crohn's disease.

UK Boy Enrolls in Global Trial for Novel Low-Grade Glioma Drug

A six-year-old boy from Peterborough is the first UK participant in a global clinical trial for a novel drug targeting low-grade gliomas.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.